Business
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“Fractyl Health” or the “Company”), a metabolic therapeutics company
About this update from Fractyl Health, Inc.
[{"type":"text","content":"LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“Fractyl Health” or the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of Type 2 Diabetes (T2D) and obesity, today announced the appointment of Samuel Conaway to its Board of Directors. Mr. Conaway's extensive background in the commercialization of medical technologies and leadership in new product launches will provide valuable insight and experience as Fractyl Health advances through pivotal clinical studies for T2D and weight loss maintenance and continues its ongoing pilot launch and real-world registry study of Revita in Germany. \"Sam Conaway's proven track record in the successful launch of novel products and therapeutic procedures is a critical addition to our Board of Directors at this juncture,\" said Dr. Harith Rajagopalan, Co-Founder and CEO of Fractyl Health. \"As we progress with our pivotal trials and look towards the future, Sam's strategic vision and commercial acumen will be invaluable, and his appointment underscores our commitment to developing and commercializing new treatment options for people with T2D and obesity.\" Mr. Conaway currently serves as President of U.S. Sales in the Cardiology Group at Boston Scientific Corporation and as Chairman of Close the Gap, the Boston Scientific Health Equity initiative. His leadership roles have cemented his reputation as a driving force in the medical device sector. \"I am deeply honored and excited to join the Board of Directors at Fractyl Health, a company at the cutting edge of addressing some of the most pressing healthcare challenges of our time,\" said Mr. Conaway. \"Fractyl Health's novel approach has the potential to significantly impact patient lives, and I look forward to contributing my experience to support Revita through its clinical milestones and as the company seeks approval for this innovative technology.\" Mr. Conaway's expertise is expected to play a key role in Fractyl Health's ongoing efforts to complete its pivotal clinical studies in T2D and weight loss maintenance. About Fractyl Health Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including T2D and obesity. Despite advances in treatment over the last 50 years, T2D and obesi...